Chris De Savi joins Curie Bio as CSO partner to biotech founders

Curie Bio,  which launched last month as a new venture model in biotech, today announced that Chris De Savi, an expert practitioner of drug discovery and drug discovery executive, has joined the firm as a CSO Partner.

Mr De Savi most recently was head of drug discovery at Kymera Therapeutics (Nasdaq: KYMR), and prior to that was a drug hunter at both Blueprint Medicines (Nasdaq: BPMC) and AstraZeneca (LSE: AZN).

Mr De Savi has contributed to the development of several drug development candidates, including Blueprint Medicines' next-generation EGFR candidate BLU-945, AstraZeneca's CDK9 inhibitor AZD4573 and AZ's oral SERD program.